A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Recruiting · Phase 3 · NCT06174987
Conditions: Advanced Cancer, Metastatic Cancer
At a glance
- Research payments reported, 2025
- $79,908
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 75
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca)
- Tested
- T-DXd (drug)
- Dates
- Started 2024-01-05; completion 2028-02-17
- Results posted
- Not yet
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study.
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $79,908 in research payments for this study in 2025 (54 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John H. Strickler, MD Hematology & Oncology · Jacksonville, FL
- Grace Wang, M.D. Hematology & Oncology · Miami, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $46,393
- Baptist Health South Florida, Inc $33,515
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.